MiMedx Group Stock

MiMedx Group EBIT

The EBIT of MiMedx Group (MDXG) as of Aug 14, 2026 is 63.89 M USD. In the previous year, EBIT was 58.87 M USD — a change of 8.53% (higher).

EBIT

63.89 MUSD

YoY

8.53%

Last updated:

In 2026, MiMedx Group's EBIT was 63.89 M USD, a 8.53% increase from the 58.87 M USD EBIT recorded in the previous year.

The MiMedx Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
37.12 base
Jan 1, 2024
58.87 base
Jan 1, 2025
63.89 base
Jan 1, 2026 (e)
19.60 base
Jan 1, 2027 (e)
22.03 base
Jan 1, 2028 (e)
24.80 base
Jan 1, 2029 (e)
27.30 base
Jan 1, 2030 (e)
30.73 base
YEAREBIT (M USD)
2030 est 30.73
2029 est 27.30
2028 est 24.80
2027 est 22.03
2026 est 19.60
2025 63.89
2024 58.87
2023 37.12
2022 -14.73
2021 -7.05
2020 -44.37
2019 -3.92
2018 -3.92
2017 46.22
2016 0.88
2015 24.36
2014 7.10
2013 -2.64
2012 -1.99
2011 -9.76
2010 -10.53
2009 -11.98
2008 -17.85
2007 -0.04
2006 -0.02
Access this data via the Eulerpool API

MiMedx Group Revenue

MiMedx Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
321.48 M USD
37.12 M USD
67.44 M USD
Jan 1, 2024
348.88 M USD
58.87 M USD
42.42 M USD
Jan 1, 2025
418.63 M USD
63.89 M USD
48.58 M USD
Jan 1, 2026 (e)
269.43 M USD
19.60 M USD
-8.61 M USD
Jan 1, 2027 (e)
302.87 M USD
22.03 M USD
11.84 M USD
Jan 1, 2028 (e)
340.92 M USD
24.80 M USD
23.76 M USD
Jan 1, 2029 (e)
375.30 M USD
27.30 M USD
29.94 M USD
Jan 1, 2030 (e)
422.50 M USD
30.73 M USD
40.43 M USD

MiMedx Group Margins

MiMedx Group stock margins

The MiMedx Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MiMedx Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MiMedx Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
83.01 %
11.55 %
20.98 %
Jan 1, 2024
82.78 %
16.87 %
12.16 %
Jan 1, 2025
82.56 %
15.26 %
11.60 %
Jan 1, 2026 (e)
82.56 %
7.27 %
-3.20 %
Jan 1, 2027 (e)
82.56 %
7.27 %
3.91 %
Jan 1, 2028 (e)
82.56 %
7.27 %
6.97 %
Jan 1, 2029 (e)
82.56 %
7.27 %
7.98 %
Jan 1, 2030 (e)
82.56 %
7.27 %
9.57 %

MiMedx Group Stock analysis

What does MiMedx Group do? MiMedx Group Inc is a biopharmaceutical company based in Marietta, Georgia that focuses on the development and marketing of tissue replacement products for chronic wounds. The company was founded in 2008 and has since experienced remarkable growth. History MiMedx was founded by Parker H. "Pete" Petit and John Daniel "Dan" Hannaford III. The company was originally established as SpineMedica Inc., which focused on manufacturing medical devices for spinal treatment. In 2010, the company changed its name to MiMedx Group Inc. and expanded its business activities into the field of regenerative medicine. In 2012, the company launched its first tissue replacement product line, EpiFix, an allogeneic epithelial cell matrix for the treatment of chronic wounds. Since then, the company has expanded its product portfolio through the development and marketing of additional tissue replacement products such as AmnioFix and EpiCord. Business Model MiMedx has a unique business model based on the distribution of tissue replacement products for chronic wounds. The company's products are manufactured and marketed through its subsidiaries MiMedx Biologics and Stability Biologics. MiMedx's business model is based on the concepts of allograft and amniotomy technology. This involves the production of products derived from placenta and umbilical cord that contain a variety of growth factors and bioactive molecules that can aid in the healing of chronic wounds. MiMedx has a strong presence in the US market and works closely with hospitals, clinics, physicians, and insurance companies to provide access to its products. Divisions MiMedx Group offers a variety of products targeting the treatment of chronic wounds. Here are some of the key divisions of the company: 1. EpiFix EpiFix is an allograft product line derived from human placental tissue. It contains a natural matrix of epithelial cells that can aid in the regeneration of skin tissue. EpiFix is used for the treatment of chronic wounds such as venous ulcers and diabetic foot ulcers. 2. AmnioFix AmnioFix is a product line derived from human umbilical cord fluid and placental tissue. It contains a mixture of growth factors and molecules that can be used in tissue and bone healing. AmnioFix is used for the treatment of chronic wounds, tendon injuries, and bone fractures. 3. EpiCord EpiCord is a product line derived from human umbilical cord tissue. It contains a natural matrix of tissues that can aid in the restoration of skin tissue. EpiCord is used for the treatment of chronic wounds, tendon injuries, and bone fractures. Products MiMedx takes pride in its range of tissue replacement products for the treatment of chronic wounds. Here are some of the key products offered by the company: 1. EpiFix VLU EpiFix VLU is a product line specifically designed for the treatment of venous ulcers. It is available in various sizes and provides a natural matrix of epithelial cells that can aid in the regeneration of skin tissue. 2. AmnioFix Injectable AmnioFix Injectable is an injectable tissue replacement product derived from human umbilical cord cells. It contains a mixture of growth factors and molecules that can aid in tissue and bone healing. 3. EpiCord EpiCord is a tissue replacement product derived from human umbilical cord tissue. It contains a natural matrix of tissues that can aid in the regeneration of skin tissue and bone. Summary Overall, MiMedx is an emerging biotechnology company that specializes in the development and marketing of tissue replacement products for chronic wounds. The company has achieved strong growth thanks to its innovative products and unique business model. With its strong presence in the US market and its focus on expanding into growing markets such as Asia and Europe, MiMedx has the potential to become a key player in the regenerative medicine industry. MiMedx Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing MiMedx Group's EBIT

MiMedx Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of MiMedx Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

MiMedx Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in MiMedx Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about MiMedx Group stock

EBIT of MiMedx Group is 63.89 M USD in 2026.

EBIT of MiMedx Group changed from 58.87 M USD to 63.89 M USD, representing a 8.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT MiMedx Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's MiMedx Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — MiMedx Group

All Key Metrics — MiMedx Group